FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and aims at treating ophthalmic diseases by subconjunctival injection. Suspension composition for subconjunctival injection into human eye contains cyclosporine A; suspending agent; osmosis-regulating agent; one or more buffers; SAS and carrier. Cyclosporine A has particle size D90 in range from 70 mcm to 100 mcm. Invention also provides two-component systems for making said suspension for subconjunctival injection and a system for delivering said suspension composition.
EFFECT: using the group of inventions enables accelerating resorption in subconjunctival administration.
25 cl, 8 dwg, 12 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
AUTOCLAVABLE FORM 2 CYCLOSPORIN A PORTION | 2012 |
|
RU2630970C2 |
COMPOSITION OF PROLONGED ACTION OF CYCLOSPORIN OF FORM 2 | 2012 |
|
RU2639393C2 |
FINAFLOXACIN SUSPENSION COMPOSITIONS | 2013 |
|
RU2693476C2 |
OPHTHALMIC COMPOSITION | 2012 |
|
RU2639472C2 |
STABLE PHARMACEUTICAL COMPOSITION WITH FIXED DOSE, CONTAINING MOMETASONE AND OLOPATADINE | 2014 |
|
RU2687551C2 |
PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLOSPORINE | 2006 |
|
RU2421209C2 |
ANESTHETIC COMPOSITION AND METHOD OF EYE ANESTHETIZATION | 2020 |
|
RU2812900C2 |
CYCLOSPORINE SUSPENSIONS A OF FORM 2 | 2012 |
|
RU2641963C2 |
MICROEMULSION COMPOSITIONS | 2019 |
|
RU2787998C1 |
CONCENTRATED PROTEIN PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2626512C2 |
Authors
Dates
2020-02-11—Published
2015-07-20—Filed